{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:56:27Z","timestamp":1781697387638,"version":"3.54.5"},"reference-count":59,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Epcoritamab, the first subcutaneous (SC) bispecific approved for relapsed\/refractory diffuse large B-cell lymphoma (R\/R-DLBCL), offers potential advantages in terms of healthcare resource utilization (HCRU) associated with its SC administration. This study aimed to estimate HCRU and associated costs of R\/R-DLBCL treatments, to inform health technology assessment agencies, institutional decision makers and healthcare professionals (HCP) from both a Canadian and Quebec perspective. Secondary objectives included using a societal perspective and estimating chair time and HCP time involved in administering treatments.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    A 1-year costing analysis was developed comparing epcoritamab to other R\/R-DLBCL treatments, including glofitamab, CAR-T cell therapies, chemotherapy, Pola-BR and Tafa-Len. HCRU and associated costs included pretreatment, administration, monitoring, and adverse event management. Acquisition costs of active treatments were excluded. Multiple time horizons were assessed. Model inputs were retrieved from product labels and validated by clinical experts to reflect practice.\n                    <jats:bold>Results:<\/jats:bold>\n                    From the Canadian and Quebec healthcare system perspective, total 1-year HCRU costs ranged from $11,009 to $54,946 and $10,041 to $54,362, respectively. Epcoritamab ranked as the second least costly comparator after chemotherapy, with notable HCRU savings driven by low administration costs of SC injections and adverse event management costs. Epcoritamab ranked similarly from a societal perspective and scenario analysis evaluating a 2-year time-horizon. Epcoritamab had the lowest annual chair time and HCP time, freeing up resources and HCP availability.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Considering the highly constrained Canadian healthcare system, SC epcoritamab offers substantial HCRU-related cost saving, chair time savings and HCP time savings when compared with other available treatments, making it an effective, efficient and patient-centric treatment option for R\/R-DLBCL in Canada.\n                  <\/jats:p>","DOI":"10.57264\/cer-2025-0187","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:18:17Z","timestamp":1776680297000},"source":"Crossref","is-referenced-by-count":0,"title":["Health care resource use in the management of patients with relapsed\/refractory diffuse large B-cell lymphoma \u2013 Canadian perspective"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5245-1178","authenticated-orcid":false,"given":"Kimberly","family":"Guinan","sequence":"first","affiliation":[{"name":"PeriPharm Inc., Montreal, Quebec, H2Y 1V3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Pelletier","sequence":"additional","affiliation":[{"name":"PeriPharm Inc., Montreal, Quebec, H2Y 1V3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Ham","sequence":"additional","affiliation":[{"name":"PeriPharm Inc., Montreal, Quebec, H2Y 1V3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4849-2442","authenticated-orcid":false,"given":"Dipti","family":"Tankala","sequence":"additional","affiliation":[{"name":"AbbVie Corporation, Saint-Laurent, Quebec, H4S 1Z1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Paul","family":"Roc","sequence":"additional","affiliation":[{"name":"AbbVie Corporation, Saint-Laurent, Quebec, H4S 1Z1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9368-7953","authenticated-orcid":false,"given":"Adi","family":"Klil-Drori","sequence":"additional","affiliation":[{"name":"AbbVie Corporation, Saint-Laurent, Quebec, H4S 1Z1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W","family":"Wang","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL 60064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[{"name":"Hematologist &amp; Medical Oncologist CHU de Qu\u00e9bec &amp; Associate clinical professor, Laval University, Qu\u00e9bec, QC, G1V 4W6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7750-2733","authenticated-orcid":false,"given":"David","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Division of Hematology, Dalhousie University &amp; QEII Health Sciences Centre, Halifax, NS, B3H 3A7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0791-2518","authenticated-orcid":false,"given":"Jean","family":"Lachaine","sequence":"additional","affiliation":[{"name":"PeriPharm Inc., Montreal, Quebec, H2Y 1V3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Barakat","sequence":"additional","affiliation":[{"name":"AbbVie Corporation, Saint-Laurent, Quebec, H4S 1Z1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_9_3_2","unstructured":"Canadian Cancer Society. Diffuse large B-cell lymphoma 2023. https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/non-hodgkin-lymphoma\/what-is-non-hodgkin-lymphoma\/diffuse-large-b-cell-lymphoma"},{"key":"e_1_3_9_4_2","unstructured":"Lymphoma Canada. Diffuse large B cell lymphoma (DLBCL) 2023. https:\/\/www.lymphoma.ca\/diffuse-large-b-cell-lymphoma\/"},{"key":"e_1_3_9_5_2","unstructured":"Sapkota SSH. Non-Hodgkin lymphoma 2023. (updated 24 February 2023). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559328\/#:\u223c:text=Overall%2C%20Non%2DHodgkin%20lymphoma%20is median%20age%20being%2067%20years"},{"key":"e_1_3_9_6_2","unstructured":"Lymphoma Canada. Canadian evidence-based guidelines for the treatment of relapsed\/refractory diffuse large B-cell lymphoma 2023. https:\/\/z9a2f9c2.rocketcdn.me\/wp-content\/uploads\/2021\/09\/LymphomaCanada_Guideline_Relapsed_Refractory_DLBCL_VF_Digital.pdf"},{"issue":"2","key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin JR","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ Survival with axicabtagene ciloleucel in large B-cell lymphoma. N. Engl. J. Med. 389(2), 148\u2013157 (2023).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont C","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 38(12), 2653\u20132662 (2024).","journal-title":"Leukemia"},{"issue":"16","key":"e_1_3_9_9_2","article-title":"Glofitamab monotherapy in pts with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal Phase II study","volume":"41","author":"Falchi L","year":"2023","unstructured":"Falchi L, Carlo-Stella C, Morschhauser F Glofitamab monotherapy in pts with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal Phase II study. J. Clin. Oncol. 41(Suppl. 16), Abstract 7550 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-Cell Lymphoma","volume":"387","author":"Dickinson MJ","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F Glofitamab for relapsed or refractory diffuse large B-Cell Lymphoma. N. Engl. J. Med. 387(24), 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_9_11_2","unstructured":"AbbVie Corporation. Product monograph including patient information: EPKINLY (epcoritamab) 2023. https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/en\/documents\/products\/EPKINLY_PM_EN.pdf"},{"key":"e_1_3_9_12_2","unstructured":"Hoffmann-La Roche Limited. Product monograph including patient medication information: Columvi (glofitamab) 2023. https:\/\/pdf.hres.ca\/dpd_pm\/00070059.PDF"},{"issue":"5","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/08404704231183863","article-title":"Canada's primary care crisis: Federal Government Response","volume":"36","author":"Flood CM","year":"2023","unstructured":"Flood CM, Thomas B, McGibbon E. Canada's primary care crisis: Federal Government Response. Healthc. Manage. Forum 36(5), 327\u2013332 (2023).","journal-title":"Healthc. Manage. Forum"},{"key":"e_1_3_9_14_2","unstructured":"Canadian Medical Association. Canada's health care crisis: what we need now 2022. https:\/\/www.cma.ca\/latest-stories\/canadas-health-care-crisis-what-we-need-now"},{"issue":"1","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1182\/blood-2023-181259","article-title":"Practice efficiency associated with epcoritamab for the treatment ofpatients with relapsed or refractorye B-cell lymphoma from an institutional perspective","volume":"142","author":"Lei M","year":"2023","unstructured":"Lei M, Li Q, O'Day K, Meyer K, Wang A, Jun M. Practice efficiency associated with epcoritamab for the treatment ofpatients with relapsed or refractorye B-cell lymphoma from an institutional perspective. Blood 142(Suppl. 1), 7254 (2023).","journal-title":"Blood"},{"key":"e_1_3_9_16_2","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH reimbursement recommendation: lisocabtagene maraleucel (Breyanzi)."},{"key":"e_1_3_9_17_2","unstructured":"Novartis Pharmceuticals Canada Inc. Product monograph including patient medication information: KYMRIAH (Tisagenlecleucel). (2018)."},{"key":"e_1_3_9_18_2","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH reimbursement recommendation: axicabtagene ciloleucel (Yescarta). (June 2023)."},{"key":"e_1_3_9_19_2","unstructured":"Hoffmann-La Roche Limited. Product monograph including patient medication information: POLIVY (Polatuzumab vedotin for injection). (2023)."},{"key":"e_1_3_9_20_2","unstructured":"Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) finale recommendation: polatuzumab vedotin (Polivy). (2021)."},{"key":"e_1_3_9_21_2","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH reimbursement recommendation: tafasitamab (Minjuvi). (October 2022)."},{"key":"e_1_3_9_22_2","unstructured":"Institut National d'excellence and sante et services sociaux (INESSS). Avis transmis au ministre: MINJUVI (Lymphome diffus \u00e0 grandes cellules B). (October 2022)."},{"key":"e_1_3_9_23_2","unstructured":"Institut National d'excellence and sante et services sociaux (INESSS). Avis transmis au ministre: POLIVY (Lymphome diffus \u00e0 grandes cellules B). (May 2021)."},{"key":"e_1_3_9_24_2","unstructured":"Statistics Canada. Consumer Price Index by product group monthly percentage change not seasonally adjusted Canada provinces Whitehorse Yellowknife and Iqaluit 2023. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000413"},{"issue":"2","key":"e_1_3_9_25_2","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaoncol.2019.3869","article-title":"Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review","volume":"6","author":"Locke F","year":"2020","unstructured":"Locke F, Go W, Neelapu S. Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review. JAMA Oncol. 6(2), 281\u2013290 (2020).","journal-title":"JAMA Oncol."},{"key":"e_1_3_9_26_2","unstructured":"Ontario Ministry of Health and Long-Term Care. Laboratories and diagnostics branch. Schedule of benefits for laboratory services (Effective 24 July 2023). https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/lab\/sob_lab_2023.pdf"},{"key":"e_1_3_9_27_2","unstructured":"R\u00e9gie de l'assurance maladie du Quebec (RAMQ). Manuel des m\u00e9decins sp\u00e9cialistes \u2013 R\u00e9mun\u00e9ration \u00e0 l'acte 2023. https:\/\/www.ramq.gouv.qc.ca\/fr\/professionnels\/medecins-specialistes\/manuels\/Pages\/remuneration-acte.aspx"},{"key":"e_1_3_9_28_2","unstructured":"Government of Canada. Wages for pharmacists (NOC 3131). Wage data updated on November 17th 2021. https:\/\/www.jobbank.gc.ca\/wagereport\/occupation\/18196"},{"key":"e_1_3_9_29_2","unstructured":"Government of Canada. Wages Registered Nurse in Canada 2022. https:\/\/www.jobbank.gc.ca\/marketreport\/wages-occupation\/993\/ca"},{"issue":"2","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3111\/13696998.2015.1105230","article-title":"Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada","volume":"19","author":"Pettigrew M","year":"2016","unstructured":"Pettigrew M, Kavan P, Surprenant L, Lim HJ. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada. J. Med. Econ. 19(2), 135\u2013147 (2016).","journal-title":"J. Med. Econ."},{"key":"e_1_3_9_31_2","unstructured":"Statistics Canada. Employee wages by industry annual (Table: 14-10-0064-01) 2023. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/cv.action?pid=1410006401"},{"key":"e_1_3_9_32_2","unstructured":"Statistics Canada. Average usual and actual hours worked in a reference week by type of work (full- and part-time) annual (Table: 14-10-0043-01) 2023. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1410004301"},{"key":"e_1_3_9_33_2","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Axicabtagene ciloleucel for diffuse large B-Cell lymphoma: economic review report. (2019)."},{"issue":"10254","key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson JS","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254), 839\u2013852 (2020).","journal-title":"Lancet"},{"issue":"1","key":"e_1_3_9_35_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster SJ","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N. Engl. J. Med. 380(1), 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"e_1_3_9_36_2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu SS","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma. N. Engl. J. Med. 377(26), 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"e_1_3_9_37_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, Phase I\u2013II trial","volume":"20","author":"Locke FL","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, Phase I\u2013II trial. Lancet Oncol. 20(1), 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"e_1_3_9_38_2","unstructured":"Ontario Ministry of Health and Long-Term Care. Ontario drug benefit (ODB) formulary 2023. https:\/\/www.formulary.health.gov.on.ca\/formulary\/"},{"key":"e_1_3_9_39_2","unstructured":"R\u00e9gie de l'assurance maladie du Quebec (RAMQ). Liste des medicaments. (6 July 2023)."},{"key":"e_1_3_9_40_2","unstructured":"IQVIA Delta PA. (12 July 2023)."},{"key":"e_1_3_9_41_2","unstructured":"Mayo clinic. CAR-T cell therapy program. https:\/\/www.mayoclinic.org\/departments-centers\/car-t-cell-therapy-program\/sections\/gnc-20405547#:\u223c:text=Infusion%3A%20The%20infusion%20of%20CAR the%20CAR%20%2DT%20cell%20infusion"},{"key":"e_1_3_9_42_2","unstructured":"Cancer Care Ontario. R-GemOx Regimen 2022. https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/monograph\/67996"},{"key":"e_1_3_9_43_2","unstructured":"Cancer Care Ontario. Drug formulary - BEND+POLA+RITU. (2022). https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/monograph\/62866"},{"key":"e_1_3_9_44_2","unstructured":"Cancer Care Ontario. Drug formulary - LENA+TAFA. (2022). https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens\/monograph\/71931"},{"key":"e_1_3_9_45_2","unstructured":"Canadian Institute for Health Information. Patient cost estimator. (2019). https:\/\/www.cihi.ca\/en\/patient-cost-estimator"},{"key":"e_1_3_9_46_2","unstructured":"Cancer Care Ontario. Drug formulary: funded evidence-informed regimens 2023. https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens"},{"issue":"2","key":"e_1_3_9_47_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma","volume":"38","author":"Sehn LH","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma. J. Clin. Oncol. 38(2), 155\u2013165 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"e_1_3_9_48_2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles G","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 21(7), 978\u2013988 (2020).","journal-title":"Lancet Oncol."},{"issue":"5","key":"e_1_3_9_49_2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00280-009-0941-9","article-title":"Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory\/relapsing B-cell lymphoma","volume":"64","author":"Corazzelli G","year":"2009","unstructured":"Corazzelli G, Capobianco G, Arcamone M Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory\/relapsing B-cell lymphoma. Cancer Chemother. Pharmacol. 64(5), 907\u2013916 (2009).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"e_1_3_9_50_2","unstructured":"Ontario Ministry of Health and Long-Term Care. Ontario case costing analysis tool. (2018)."},{"key":"e_1_3_9_51_2","unstructured":"BC Cancer. Tocilizumab (interim monograph) 2021. http:\/\/www.bccancer.bc.ca\/drug-database-site\/Drug%20Index\/Tocilizumab_interim%20monograph.pdf"},{"key":"e_1_3_9_52_2","unstructured":"BC Cancer. BC cancer guidelines for prevention and treatment of chemotherapy-induced nausea and vomiting in adults 2022. http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Supportive%20Care\/SCNAUSEA_Protocol.pdf"},{"key":"e_1_3_9_53_2","unstructured":"Cancer Care Ontario. Drug Formulary - Regimens 2022. https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens?f%5B0%5D=field_type_of_cancer%3A626"},{"issue":"2","key":"e_1_3_9_54_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3390\/curroncol28020119","article-title":"Evaluating the indirect costs of care associated with salvage chemotherapy for relapsed and refractory aggressive-histology lymphoma: a subset analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial","volume":"28","author":"Prica A","year":"2021","unstructured":"Prica A, Hay AE, Crump M Evaluating the indirect costs of care associated with salvage chemotherapy for relapsed and refractory aggressive-histology lymphoma: a subset analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Curr. Oncol. 28(2), 1256\u20131261 (2021).","journal-title":"Curr. Oncol."},{"key":"e_1_3_9_55_2","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH reimbursement recommendation (Draft): epcoritamab (Epkinly). (2024)."},{"issue":"6","key":"e_1_3_9_56_2","doi-asserted-by":"crossref","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","article-title":"Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries","volume":"11","author":"De Cock E","year":"2016","unstructured":"De Cock E, Kritikou P, Sandoval M Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS ONE 11(6), e0157957 (2016).","journal-title":"PLoS ONE"},{"key":"e_1_3_9_57_2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20\u00fe diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)","volume":"28","author":"Rummel M","year":"2017","unstructured":"Rummel M, Kim TM, Aversa F Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20\u00fe diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann. Oncol. 28, 836\u2013842 (2017).","journal-title":"Ann. Oncol."},{"key":"e_1_3_9_58_2","volume-title":"Troubles in Canada's health workforce: the why, the where, and the way out of shortages","author":"Drummond D","year":"2022","unstructured":"Drummond D, Sinclair D, Gratton J. Troubles in Canada's health workforce: the why, the where, and the way out of shortages. CD Howe Institute, Canada (2022)."},{"key":"e_1_3_9_59_2","unstructured":"Institut national d'excellence en sant\u00e9 et services sociaux (INESSS). Tisagenlecleucel pour le traitement du lymphome diffus \u00e0 grandes cellules B r\u00e9cidivant ou r\u00e9fractair. (2019). https:\/\/www.inesss.qc.ca\/fileadmin\/doc\/INESSS\/Rapports\/Therapies_cellulaires\/INESSS_Avis_Kymriah_LDGCB.pdf"},{"key":"e_1_3_9_60_2","unstructured":"nCanadian Institute for Health Informatio. Care in Canadian ICUs. (2016). https:\/\/secure.cihi.ca\/free_products\/ICU_Report_EN.pdf"},{"key":"e_1_3_9_61_2","unstructured":"Statistics Canada. Labour force characteristics by province monthly seasonally adjusted - Table: 14-10-0287-03. (2023). https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1410028703"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:21:12Z","timestamp":1781695272000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.57264\/cer-2025-0187"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0187","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e250187"}}